Form 4: Sangamo Therapeutics Executive Disposes Shares for Tax Withholding

Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, disposed of 6,708 shares of common stock for mandatory tax withholding related to restricted stock unit vesting.

Summary

• Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, disposed of 6,708 shares of common stock on July 22, 2025.
• The shares were surrendered at a price of $0.4798 per share solely for mandatory tax withholding purposes upon the vesting of restricted stock units (RSUs).
• This transaction was not a discretionary trade by Mr. Davis but a required action under the company's Amended and Restated 2018 Equity Incentive Plan.
• Following this transaction, Mr. Davis beneficially owns 201,945 shares of Sangamo Therapeutics common stock.
• Remaining RSU grants include 37,500 shares from a January 22, 2024 grant vesting quarterly through January 22, 2026; 6,065 shares from a February 24, 2023 grant vesting quarterly through February 24, 2026; and 49,726 shares from a February 25, 2025 grant vesting one-fourth on February 25, 2026, with the remainder in eight successive equal quarterly installments thereafter.

Sentiment

Score: 5

Explanation: The filing is neutral as it reports a routine, non-discretionary transaction for tax withholding purposes related to RSU vesting. It does not indicate any positive or negative discretionary actions or significant changes in company outlook.

Positives

• The transaction is a routine, non-discretionary event related to RSU vesting, indicating the executive is receiving compensation as planned.

Negatives

• The disposition of shares, while for tax purposes, reduces the executive's direct shareholding by 6,708 shares.

Future Outlook

The filing indicates future vesting schedules for Gregory D. Davis's restricted stock units, with installments continuing through January 22, 2026, February 24, 2026, and quarterly thereafter for a grant made on February 25, 2025.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically the disposition of shares for tax withholding upon RSU vesting. It does not provide information relevant to broader industry trends or competitive analysis within the biotechnology or pharmaceutical sectors. Such transactions are common across all industries for executives receiving equity compensation.

Comparison to Industry Standards

• This filing details a standard, non-discretionary insider transaction for tax withholding purposes, which is a common practice for equity compensation across publicly traded companies. There are no specific comparable companies, projects, or results to list as this is an individual compensation event.

Corporate Governance

Related Party Transactions

• The transaction involves the surrender of shares to the Issuer (Sangamo Therapeutics, Inc.) for mandatory tax withholding purposes, which is a standard process for equity compensation under the company's incentive plan.

Stakeholder Impact

• Shareholders: Minimal direct impact as it is a routine, non-discretionary transaction for tax withholding, not a discretionary sale that would signal a change in executive confidence.
• Employees: Demonstrates the ongoing operation of the company's equity incentive plan for executives.

Next Steps

• Future vesting installments of Gregory D. Davis's January 22, 2024 RSU grant through January 22, 2026.
• Future vesting installments of Gregory D. Davis's February 24, 2023 RSU grant through February 24, 2026.
• Future vesting installments of Gregory D. Davis's February 25, 2025 RSU grant, with one-fourth vesting on February 25, 2026, and the remainder in eight successive equal quarterly installments thereafter.

Key Dates

Keywords

Sangamo Therapeutics, SGMO, Form 4, Insider Transaction, Restricted Stock Units, RSU, Tax Withholding, Equity Incentive Plan, Gregory D. Davis, Biotechnology, Pharmaceuticals